Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

Rigel completed enrolment for the dose escalation phase in July 2025 and expects to share updated data later this year.

Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel ...

The U.S. National Institutes of Health on Thursday launched a clinical trial of fostamatinib, currently used to treat a blood platelet-destroying autoimmune disorder, in patients hospitalized with ...

Rigel plans to present updated data from the dose escalation phase later this year. The scheduled FDA consultations could prove pivotal in determining the compound's future. Technical chart analysis ...

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) shares are on the move Wednesday after the company reported fourth-quarter results well above analyst expectations. What Happened: Rigel reported fourth-quarter ...

RIGL hoped to expand the label of its drug Tavalisse (fostamatinib), but the failure of the drug in phase 3 appeared to scupper its chances. RIGL sought guidance to see if a reanalysis of the failed ...